On a scale of 0 to 100, Apimeds Pharmaceuticals holds a performance score of 2. The firm shows a Beta (market volatility) of 1.72, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Apimeds Pharmaceuticals will likely underperform. Please check Apimeds Pharmaceuticals' sortino ratio, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Apimeds Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
Soft
Weak
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Apimeds Pharmaceuticals US, are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively inconsistent basic indicators, Apimeds Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Apimeds Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 193.00 in Apimeds Pharmaceuticals US, on September 26, 2025 and sell it today you would lose (17.00) from holding Apimeds Pharmaceuticals US, or give up 8.81% of portfolio value over 90 days. Apimeds Pharmaceuticals US, is currently generating 0.2806% in daily expected returns and assumes 9.3983% risk (volatility on return distribution) over the 90 days horizon. In different words, 84% of stocks are less volatile than Apimeds, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Given the investment horizon of 90 days Apimeds Pharmaceuticals is expected to generate 13.2 times more return on investment than the market. However, the company is 13.2 times more volatile than its market benchmark. It trades about 0.03 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.12 per unit of risk.
Apimeds Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Apimeds Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Apimeds Pharmaceuticals US,, and traders can use it to determine the average amount a Apimeds Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0299
Best Portfolio
Best Equity
Good Returns
Average Returns
Small Returns
APUS
Cash
Small Risk
Average Risk
High Risk
Huge Risk
Negative Returns
Based on monthly moving average Apimeds Pharmaceuticals is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Apimeds Pharmaceuticals by adding it to a well-diversified portfolio.
Apimeds Pharmaceuticals Fundamentals Growth
Apimeds Stock prices reflect investors' perceptions of the future prospects and financial health of Apimeds Pharmaceuticals, and Apimeds Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Apimeds Stock performance.
Assessing Apimeds Pharmaceuticals' fundamental ratios provides investors with valuable insights into Apimeds Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Apimeds Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Apimeds Pharmaceuticals performance evaluation
Checking the ongoing alerts about Apimeds Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Apimeds Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Apimeds Pharmaceuticals had very high historical volatility over the last 90 days
Apimeds Pharmaceuticals may become a speculative penny stock
Apimeds Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (1.39 M) with profit before overhead, payroll, taxes, and interest of 0.
Apimeds Pharmaceuticals generates negative cash flow from operations
About 82.0% of the company shares are held by company insiders
Evaluating Apimeds Pharmaceuticals' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Apimeds Pharmaceuticals' stock performance include:
Analyzing Apimeds Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Apimeds Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
Examining Apimeds Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Apimeds Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Apimeds Pharmaceuticals' management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of Apimeds Pharmaceuticals' stock. These opinions can provide insight into Apimeds Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Apimeds Pharmaceuticals' stock performance is not an exact science, and many factors can impact Apimeds Pharmaceuticals' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Additional Tools for Apimeds Stock Analysis
When running Apimeds Pharmaceuticals' price analysis, check to measure Apimeds Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apimeds Pharmaceuticals is operating at the current time. Most of Apimeds Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apimeds Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apimeds Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apimeds Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.